- Email: [email protected]
5202252 Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
223
PATENT ABSTRACTS like polypeptides also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-l, by a molecule of various chromatographic steps. This invention also relates to DNA molecules encoding human somatomedin carrier proteinlike polypeptides, recombinant DNA molecules, hosts, processes for producing carrier proteinlike polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human cartier protein or a human carrier protein subunit capable of binding somatomedins. The DNA molecules, recombinant DNA molecules, hosts, and processes of this invention may be used in the production of polypeptides useful in a variety of therapeutic, diagnostic, and other useful applications.
5202113 PLAQUF_~-INHIBITING PROTEIN FROM BACTEROIDES LOESCHEI AND METHODS FOR USING THE SAME Jac London assigned to The United States of America as represented by the Department of Health and Human Services A purified, characterized surface protein from Bacteroides loesehei is an adhesin which is useful in inhibiting plaque formation. The adhesin is also useful in a diagnostic assay for gingivitis, a diagnostic indicator for changes in the surface components of certain human tissues, and as a binding agent to purify polysaccharides.
5202234 MYOCARDIAL INFARCTION IMMUNOASSAY Vipin D Shah, Shing-Erh Yen, Gerald M Anchin assigned to Internatioul Immunoassay Laboratories Inc Methods and reagents for determining the lapse of time since an acute disease event, such as the
occurrence of a myocardial infarction, are presented. A serum sample is assayed to determine the concentration of two analyte sets. From these measurements, the time of the acute event can be more accurately determined. Novel antibodies, labeled and insolubilized derivatives of these antibodies, labeled proteins, and kits containing one or more of these reagents are also described.
5202241 A N T I B I O T I C G E 2270 Enrico Selva, Nicoletta Montanini, Graziella Beretta, Beth P Goldstein, Maurizi Denaro, Lund, assigned to Gruppo Lepetit S p A The present invention is directed to a new antibiotic substance denominated antibiotic GE 2270, the addition salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them.
5202252 MONOCLONAL ANTIBODIES AGAINST LENS EPITHELIAL CELLS AND METHODS FOR PREVENTING PROLIFERATION OF REMNANT LENS EPITHELIAL CELLS AFTER EXTRACAPSULAR EXTRACTION Jared M Emery, Dominic M Laln, Peter J Kelleher, Land,assigned to Houston Biotechnology Inc Compositions and methods for their use are provided for preventing proliferation of remnant lens epithelial cells following extracapsular extraction. Complement-fixing monoclonal antibodies specific for lens epithelial cells are introduced into the anterior chamber of the eye. Following binding of the monoclonal antibody to any lens epithelial cells, complement is introduced into the anterior chamber effecting lysis of the remnant lens epithelial cells. The method may be used at the time of extracapsular cataract extraction or may be used subsequently to remove a second cataract resulting from proliferation of remnant lens epithelial cells.
PATENT ABSTRACTS like polypeptides also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-l, by a molecule of various chromatographic steps. This invention also relates to DNA molecules encoding human somatomedin carrier proteinlike polypeptides, recombinant DNA molecules, hosts, processes for producing carrier proteinlike polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human cartier protein or a human carrier protein subunit capable of binding somatomedins. The DNA molecules, recombinant DNA molecules, hosts, and processes of this invention may be used in the production of polypeptides useful in a variety of therapeutic, diagnostic, and other useful applications.
5202113 PLAQUF_~-INHIBITING PROTEIN FROM BACTEROIDES LOESCHEI AND METHODS FOR USING THE SAME Jac London assigned to The United States of America as represented by the Department of Health and Human Services A purified, characterized surface protein from Bacteroides loesehei is an adhesin which is useful in inhibiting plaque formation. The adhesin is also useful in a diagnostic assay for gingivitis, a diagnostic indicator for changes in the surface components of certain human tissues, and as a binding agent to purify polysaccharides.
5202234 MYOCARDIAL INFARCTION IMMUNOASSAY Vipin D Shah, Shing-Erh Yen, Gerald M Anchin assigned to Internatioul Immunoassay Laboratories Inc Methods and reagents for determining the lapse of time since an acute disease event, such as the
occurrence of a myocardial infarction, are presented. A serum sample is assayed to determine the concentration of two analyte sets. From these measurements, the time of the acute event can be more accurately determined. Novel antibodies, labeled and insolubilized derivatives of these antibodies, labeled proteins, and kits containing one or more of these reagents are also described.
5202241 A N T I B I O T I C G E 2270 Enrico Selva, Nicoletta Montanini, Graziella Beretta, Beth P Goldstein, Maurizi Denaro, Lund, assigned to Gruppo Lepetit S p A The present invention is directed to a new antibiotic substance denominated antibiotic GE 2270, the addition salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them.
5202252 MONOCLONAL ANTIBODIES AGAINST LENS EPITHELIAL CELLS AND METHODS FOR PREVENTING PROLIFERATION OF REMNANT LENS EPITHELIAL CELLS AFTER EXTRACAPSULAR EXTRACTION Jared M Emery, Dominic M Laln, Peter J Kelleher, Land,assigned to Houston Biotechnology Inc Compositions and methods for their use are provided for preventing proliferation of remnant lens epithelial cells following extracapsular extraction. Complement-fixing monoclonal antibodies specific for lens epithelial cells are introduced into the anterior chamber of the eye. Following binding of the monoclonal antibody to any lens epithelial cells, complement is introduced into the anterior chamber effecting lysis of the remnant lens epithelial cells. The method may be used at the time of extracapsular cataract extraction or may be used subsequently to remove a second cataract resulting from proliferation of remnant lens epithelial cells.